The Efficacy and Safety of Elritercept in Adult Participants with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) with Anemia (RENEW)

Phase 3

Recruiting

• Conditions: Myelodysplastic Syndromes
• Interventions: Biological: KER-050; Drug: Placebo

• Registration Number: NCT06499285
• Lead Sponsor: Keros Therapeutics, Inc.

Brief Summary

This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk MDS, or more recently defined as myelodysplastic neoplasms, with or without ring sideroblasts. The study is divided into the Screening Period, Double-blind Treatment Period, Safety Follow-Up Period and Long-term Follow-up Period. Approximately 255 participants will be enrolled, randomized 2:1 to receive either elritercept or placebo.

Detailed Description

This is a Phase 3, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of KER-050 versus placebo. KER-050 an investigational medicinal product being developed for the treatment of anemia in adult participants with a diagnosis of lower-risk myelodysplastic neoplasms/syndromes. After all required Screening Period assessments are completed, and eligibility is confirmed, participants will be randomized and enter the Primary Phase of the Double-Blind Treatment Period. Participants will be randomly assigned in a 2:1 ratio to receive either KER-050 or placebo subcutaneously (SC) every 4 weeks (Q4W). Participants will be stratified according to their RS status (RS-positive versus non-RS) and baseline transfusion burden (LTB versus HTB). The Primary Phase of the Double-blind Treatment Period will last 24 weeks. The Secondary Phase of the Double-Blind Treatment Period will last an additional 24 weeks. During the Secondary Phase of the Double-Blind Treatment Period, all participants will continue to receive the same double-blind treatment they received during the Primary Phase. Study visits will occur approximately every 2 weeks from Cycle 1 through Cycle 6 and every 4 weeks from Cycle 7 through the remainder of the Double-Blind Treatment Period. During the Extension Phase of the Double-Blind Treatment Period, all eligible participants will continue to receive the same double-blind treatment they received during the Primary and Secondary Phases. Participants will continue in the Extension Phase until they individually discontinue or until the study is unblinded. For participants to remain on double-blind treatment, they must meet the criteria outlined in the MDS disease assessment criteria every 24 weeks. Based on the outcome of the Week 24 MDS disease assessment, participants will either continue in the Extension Phase of the Double-blind Treatment Period or will be discontinued from treatment and proceed to End of Treatment and then into the Safety Follow-up Period. The Safety Follow-Up Period will extend from the last dose of study treatment through 8 weeks after the last dose of study treatment. Study visits should occur every 4 weeks within the Safety Follow-Up Period. Long-term follow-up will take place quarterly after a participant has completed the Safety Follow-Up Period. Long-term follow-up will continue for 5 years from the first dose of study treatment or 3 years after the last dose, whichever is longer, or until a participant is deceased, is lost to follow-up, withdraws consent, or the study closes, whichever is earliest.

Study Timeline

• Study First Submitted: 2024-07-05
• Study First Submitted QC: 2024-07-11
• Study First Posted: 2024-07-12
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-06
• Last Update Posted: 2025-01-08
• Study Start: 2025-02
• Primary Completion: 2028-03
• Study Completion: 2032-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 225

Inclusion Criteria

• Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information and/or protected personal data in accordance with national and local study participant data protections and privacy regulations.

• Male or female ≥ 18 years of age at the time of signing informed consent.

• Diagnosis of MDS with or without RS (as determined in an evaluable bone marrow aspirate, read by an independent central reader to confirm diagnosis at Screening) according to the World Health Organization 2016 classification that meets the IPSS-R classification of very low, low, or intermediate risk disease.

• Transfusion dependence assessed in the 16 weeks immediately preceding randomization in two 8-week blocks, classified as either:

  a. LTB, defined as 4 to 7 RBC units per 16 weeks; or b. HTB, defined as ≥ 8 RBC units per 16 weeks; and c. For all participants: i. Only transfusion events for a pretransfusion Hgb < 10 g/dL are counted toward eligibility; ii. At least 1 transfusion event in each 8-week period and a minimum of 2 transfusion events separated by ≥ 7 days within the 16-week period immediately preceding randomization; and iii. No consecutive 56-day period can be RBC transfusion-free during the 16-week period immediately preceding randomization.

• Refractory or intolerant to prior ESA treatment (discontinued ≥ 8 weeks before randomization), or unlikely to respond to ESA treatment, defined as follows:

  a. Refractory to prior ESA treatment: documentation of nonresponse or a response that was no longer maintained with a prior ESA-containing regimen, either as a single agent or combination (e.g., with granulocyte colony-stimulating factor [G-CSF]); ESA regimen must have been either: i. Recombinant human EPO ≥ 40,000 IU/week for ≥ 8 doses or equivalent; or ii. Darbepoetin alpha ≥ 500 μg every 3 weeks for ≥ 4 doses or equivalent.

  b. Intolerant to prior ESA treatment: documentation of discontinuation of a prior ESA-containing regimen, either as a single agent or combination (e.g., with G-CSF), at any time after introduction due to intolerance or an AE.

  c. Unlikely to respond to ESA treatment: low chance of response to ESA based on an endogenous serum EPO level > 200 U/L.

• Less than 5% blasts in an evaluable bone marrow aspirate collected at Screening, read by an independent central reader.

• Eastern Cooperative Oncology Group performance status of 0 to 2

• Females of childbearing potential and sexually active males must agree to use highly effective methods of contraception

• In the opinion of the Investigator, the participant is able and willing to comply with the requirements of the protocol (e.g., all study procedures, return for follow-up visits).

Read More

Exclusion Criteria

• Del(5q) MDS or secondary MDS.

• Anemia due to any other known cause (e.g., thalassemia, hemolytic anemia, bleeding events, or deficiency of iron, B12, and/or folate).

• Receipt of RBC transfusion for any reason(s) other than underlying MDS within 16 weeks before randomization.

• Clinically significant cardiovascular disease defined as:

  1. New York Heart Association heart disease class III or IV;
  2. Fridericia corrected QT (QTcF) interval > 500 milliseconds during Screening;
  3. Mean systolic blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg during Screening; or
  4. Uncontrolled arrhythmia, myocardial infarction, or unstable angina within 6 months before Screening.

• Known ejection fraction < 35%, confirmed by a local echocardiogram performed during Screening, or a previously performed echocardiogram if collected within 6 months before Screening.

• Child-Pugh class C hepatic impairment

• Stroke, deep vein thrombosis, or pulmonary embolism within 6 months before Screening

• Any known history of AML

• Prior history of malignancies, other than MDS, unless participant has been free of the disease (including completion of any treatment, including maintenance, for prior malignancy) for ≥ 5 years. However, participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy:

  1. Basal or squamous cell carcinoma of the skin;
  2. Carcinoma in situ of the cervix;
  3. Carcinoma in situ of the breast; and/or
  4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system).

• History of solid organ or bone marrow transplantation

• Active infection requiring intravenous antibiotics within 28 days or oral antibiotics within 14 days before randomization

• Known positive for HIV, active infectious hepatitis B virus (HBV), or active infectious hepatitis C virus (HCV). Participants without known positive history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines.

• Body mass index ≥ 40 kg/m2

• Major surgery within 28 days before randomization

• History of allergy/anaphylaxis to investigational medicinal product (IMP) excipients (refer to the current elritercept IB for a list of excipients) or recombinant proteins.

• Prior use of elritercept, luspatercept, or sotatercept.

• Prior use of hypomethylating agents (HMAs), isocitrate dehydrogenase inhibitor, lenalidomide, imetelstat, or immunosuppressive therapy given for treatment of MDS.

• Iron chelation therapy initiated within 8 weeks before randomization. Participants on stable doses of iron chelation therapy for ≥ 8 weeks are allowed.

• Vitamin B12 or folate therapy initiated within 4 weeks before randomization. Participants on stable replacement doses for ≥ 4 weeks and without ongoing concurrent vitamin B12 or folate deficiency are allowed.

• Androgen use within 8 weeks before randomization. Participants on stable androgen dosing for hypogonadism for ≥ 8 weeks are allowed.

• High-dose corticosteroid use within 4 weeks before randomization. Participants on stable chronic steroid doses of prednisone ≤ 10 mg/day or corticosteroid equivalent for ≥ 4 weeks are allowed.

• Treatment with any investigational drug within 28 days before Screening or, if the half-life of the product is known, within 5 times the half-life before Screening, whichever is longer.

• Ongoing participation in another interventional clinical study.

• Serum EPO level > 500 U/L

• Platelet count ≥ 450 × 10^9/L or ≤ 25 × 10^9/L.

• Absolute neutrophil count ≤ 500/mL

• Serum aspartate aminotransferase or alanine aminotransferase ≥ 3 × the upper limit of normal

• Total bilirubin ≥ 2 × ULN unless attributable to Gilbert's syndrome

• Ferritin ≤ 50 μg/L

• Folate ≤ 2.0 ng/mL.

• Vitamin B12 ≤ 200 pg/mL.

• Estimated glomerular filtration rate < 40 mL/min/1.73m2 as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (National Kidney Foundation 2021; Delgado 2022)

• Pregnant or lactating female

• Any other condition not specifically noted above that, in the opinion of the Investigator, would preclude the participant from participating in the study or could confound interpretation of data from the study.

• Investigational site staff members directly involved in the conduct of the study and site staff members otherwise supervised by the Investigator, employees of the Sponsor or contract research organization (CRO) directly involved in the conduct of the study, or immediate family members (defined as a spouse, parent, child, or sibling, whether biological or legally adopted).

• For Participants in France: Persons under court protection, persons not affiliated with a social security system, and protected adults (per applicable French law [Art. L. 1121-6, Art. L. 1121-8, Art. L. 1121-8-1]).

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental: KER-050 (N=150)	KER-050	KER-050 will be administered subcutaneously every 4 weeks. The Primary Phase of the Double-Blind Treatment Period will last 24 weeks. Based on the outcome of the MDS Disease Assessment approximately 24 calendar weeks after Cycle 1 Day 1, participants will either continue in the Secondary Phase or be discontinued from treatment. During the Secondary Phase of the Double-Blind Treatment Period, all participants will continue to receive the same double-blind treatment they received during the Primary Phase, which will last 24 weeks. The second MDS Disease Assessment should be completed approximately 48 calendar weeks after C1D1 to determine whether the participant will enter the Extension Phase or be discontinued from treatment. During the Extension Phase of the Double-Blind Treatment Period, all participants will continue to receive the same double-blind treatment that they received during the Primary and Secondary Phases.
Placebo Comparator (N=70)	Placebo	Placebo will be administered subcutaneously every 4 weeks. The Primary Phase of the Double-Blind Treatment Period will last 24 weeks. Based on the outcome of the MDS Disease Assessment approximately 24 calendar weeks after Cycle 1 Day 1, participants will either continue in the Secondary Phase or be discontinued from treatment. During the Secondary Phase of the Double-Blind Treatment Period, all participants will continue to receive the same double-blind treatment they received during the Primary Phase, which will last 24 weeks. The second MDS Disease Assessment should be completed approximately 48 calendar weeks after C1D1 to determine whether the participant will enter the Extension Phase or be discontinued from treatment. During the Extension Phase of the Double-Blind Treatment Period, all participants will continue to receive the same double-blind treatment that they received during the Primary and Secondary Phases.

Primary Outcome Measures

Name	Time	Method
Efficacy evaluation of KER-050: Proportion of participants achieving TI for ≥ 8 weeks	from baseline through week 24	To evaluate the efficacy of KER-050 in reducing RBC transfusions

Secondary Outcome Measures

Name	Time	Method
Efficacy evaluation of KER-050: Proportion of participants achieving TI for ≥ 24 weeks	from baseline through week 48	To evaluate the efficacy of KER-050 in reducing RBC transfusions over longer intervals
Efficacy evaluation of KER-050: Proportion of participants with HTB achieving TI for ≥ 8 weeks	from baseline through week 24	To evaluate the efficacy of KER-050 in reducing RBC transfusions in participants with HTB
Safety and tolerability assessment of KER-050: Incidence of TEAEs and SAEs, change in clinical laboratory values, vital signs, and ECGs	change from baseline	To assess the safety and tolerability of KER-050

Trial Locations

Locations (1)

Study Site 1100; 🇺🇸 Canton, Ohio, United States